Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
2.775
+0.025 (0.91%)
Oct 13, 2025, 12:24 PM EDT - Market open

Akebia Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Oct '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
736415234106395405
Upgrade
Market Cap Growth
165.05%77.46%120.08%-73.16%-2.30%-46.16%
Upgrade
Enterprise Value
788484301121363241
Upgrade
Last Close Price
2.751.901.240.582.262.80
Upgrade
PS Ratio
3.132.591.200.361.871.37
Upgrade
PB Ratio
24.75-8.43-7.6420.305.341.63
Upgrade
P/TBV Ratio
-----8.36
Upgrade
EV/Sales Ratio
3.873.021.550.411.710.82
Upgrade
EV/EBITDA Ratio
33.74--39.44--
Upgrade
Debt / Equity Ratio
6.70-3.84-4.7230.072.560.51
Upgrade
Debt / EBITDA Ratio
6.91--18.82--
Upgrade
Asset Turnover
0.720.690.650.660.360.42
Upgrade
Inventory Turnover
1.691.642.130.771.670.72
Upgrade
Quick Ratio
1.771.070.821.010.791.59
Upgrade
Current Ratio
1.981.411.181.431.041.99
Upgrade
Return on Equity (ROE)
----237.83%-175.37%-119.82%
Upgrade
Return on Assets (ROA)
0.88%-12.49%-9.30%-4.89%-24.27%-15.41%
Upgrade
Return on Capital (ROIC)
1.69%-22.81%-20.14%-10.17%-44.71%-24.88%
Upgrade
Earnings Yield
-5.00%-16.74%-22.23%-88.77%-71.32%-95.09%
Upgrade
FCF Yield
-0.35%-9.82%-10.01%-69.03%-63.99%-27.35%
Upgrade
Buyback Yield / Dilution
-16.95%-12.53%-2.56%-10.14%-19.85%-16.95%
Upgrade
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q